Stocktoria
Biomea Fusion, Inc. BMEA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-04-16
Biomea Fusion, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $62.0M | $118.1M | $102.5M | $62.7M | $28.0M |
| Operating income | -$83.5M | -$144.1M | -$126.1M | -$83.6M | -$41.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$61.8M | -$138.4M | -$117.3M | -$81.8M | -$41.6M |
| EPS (diluted) | $-1.18 | $-3.83 | $-3.44 | $-2.80 | $-1.74 |
| Operating cash flow | -$70.4M | -$119.9M | -$96.6M | -$62.4M | -$35.4M |
| Free cash flow | — | -$120.3M | -$100.0M | -$63.4M | -$38.6M |
| Cash & equivalents | $55.8M | $58.3M | $176.9M | $111.9M | $145.7M |
| Total assets | $58.6M | $79.9M | $199.9M | $129.3M | $185.7M |
| Total liabilities | $29.0M | $28.4M | $30.7M | $20.8M | $6.9M |
| Shareholders' equity | $29.6M | $51.6M | $169.2M | $108.5M | $178.8M |
Source: SEC EDGAR filings · CIK 0001840439 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.